Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2019-05-20 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
BioArctic erhåller milstolpsersättning om 15 MEUR från Eisai då den bekräftande Fas 3-studien med BAN2401 i tidig Alzheimers sjukdom startat
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by "Pressmeddelande") announcing that BioArctic will receive a milestone payment of 15 MEUR from its partner Eisai because the Phase 3 confirmatory study (Clarity AD) for BAN2401 in early Alzheimer's disease has started (first patient dosed). This is a specific corporate event announcement related to a partnership milestone payment and clinical trial progress, not a comprehensive annual report (10-K), an earnings release (ER), or a formal regulatory filing like a DVA or DIRs. It is a general corporate announcement. Since it doesn't fit the specific categories like DIV, CAP, or MANG, and it is not a report itself but an announcement of a financial/clinical event, the most appropriate general category is Regulatory Filings (RNS), as it is a mandatory disclosure under EU market abuse regulation, but RNS serves as the best fit for significant, non-standard corporate news that isn't explicitly covered elsewhere. However, given the content is purely about a financial milestone tied to a clinical trial event, it is a significant corporate update. Since there is no specific 'Partnership Update' or 'Clinical Milestone' code, RNS is the fallback for significant regulatory disclosures that don't fit the other specific types. Given the nature of the announcement (milestone payment triggered by clinical trial start), it is a material event disclosure.
2019-05-20 Swedish
BioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a specific corporate event: BioArctic receiving a MEUR 15 milestone payment from Eisai because the first patient was dosed in the BAN2401 confirmatory Phase 3 study. This is a time-sensitive announcement regarding financial milestones and clinical trial progress, typical of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it details a specific financial event (milestone payment received, contributing to Q2 2019 revenues) and is structured as a press release, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial results/updates, even if not a full quarterly report. It is not a comprehensive report (10-K, IR), a transcript (CT), or a management discussion (MDA). Given the nature of the announcement (financial milestone tied to clinical progress), ER is the most appropriate specific code, although RNS is a close fallback.
2019-05-20 English
BioArctic - kommuniké från årsstämma 2019
AGM Information Classification · 1% confidence The document is explicitly titled "BioArctic - kommuniké från årsstämma 2019" (BioArctic - communication from the Annual General Meeting 2019) and details the decisions made during the meeting, such as the approval of the annual report, dividend distribution, election of board members, approval of remuneration guidelines, and approval of a stock option program. These are the core outcomes and announcements typically released immediately following an Annual General Meeting (AGM). Therefore, the classification is AGM-R (AGM Information). The document length (4790 chars) is substantial enough to be the primary communication, not just a brief announcement of a report (RPA/RNS).
2019-05-09 Swedish
BioArctic – report from the Annual General Meeting 2019
AGM Information Classification · 1% confidence The document is explicitly titled 'BioArctic – report from the Annual General Meeting 2019' and details resolutions adopted at the meeting, such as the adoption of the annual report, dividend allocation, discharge from liability, election of board members, auditor appointment, and approval of remuneration guidelines and an employee warrant program. These are all core activities and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information). The document length (4940 chars) is substantial enough to be the report/summary itself, not just a brief announcement of publication (RPA/RNS).
2019-05-09 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial report for BioArctic AB covering the period January to March 2019. It contains detailed financial statements, a management discussion and analysis (VD har ordet), and a project portfolio summary. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2019
2019-05-09 Swedish
Earnings Release 2019
Earnings Release Classification · 1% confidence The document text explicitly details the "Financial summary for the period January – March 2019" and includes key financial metrics, operating profit, net revenues, and earnings per share for this specific period. It also contains an "Invitation to presentation of Interim Report for the first quarter 2019" and CEO comments discussing the progress during that quarter. The content is a comprehensive financial update for a period shorter than a year (Q1 2019). This strongly indicates an Interim/Quarterly Report, which corresponds to the 'IR' filing type code. The document length is substantial (over 70k characters), confirming it is the report itself, not just an announcement (RPA/RNS). Q1 2019
2019-05-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.